These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22891797)

  • 21. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo.
    Keck PE; Calabrese JR; McIntyre RS; McQuade RD; Carson WH; Eudicone JM; Carlson BX; Marcus RN; Sanchez R;
    J Clin Psychiatry; 2007 Oct; 68(10):1480-91. PubMed ID: 17960961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-6 and total antioxidant capacity levels following
    Bortolasci CC; Voigt C; Turner A; Mohebbi M; Gray L; Dodd S; Walder K; Berk M; Cotton SM; Malhi GS; Ng CH; Dowling N; Sarris J; Dean OM
    Acta Neuropsychiatr; 2020 Dec; 32(6):313-320. PubMed ID: 32600481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial.
    Yang C; Bosker FJ; Li J; Schoevers RA
    BMC Psychiatry; 2018 Sep; 18(1):279. PubMed ID: 30176835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled study of maintenance treatment with adjunctive risperidone long-acting therapy in patients with bipolar I disorder who relapse frequently.
    Macfadden W; Alphs L; Haskins JT; Turner N; Turkoz I; Bossie C; Kujawa M; Mahmoud R
    Bipolar Disord; 2009 Dec; 11(8):827-39. PubMed ID: 19922552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-acetylcysteine for major depressive episodes in bipolar disorder.
    Magalhães PV; Dean OM; Bush AI; Copolov DL; Malhi GS; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M
    Braz J Psychiatry; 2011 Dec; 33(4):374-8. PubMed ID: 22189927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.
    Bowden CL; Calabrese JR; McElroy SL; Gyulai L; Wassef A; Petty F; Pope HG; Chou JC; Keck PE; Rhodes LJ; Swann AC; Hirschfeld RM; Wozniak PJ
    Arch Gen Psychiatry; 2000 May; 57(5):481-9. PubMed ID: 10807488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, double-blind, placebo-controlled, proof-of-concept trial of creatine monohydrate as adjunctive treatment for bipolar depression.
    Toniolo RA; Silva M; Fernandes FBF; Amaral JAMS; Dias RDS; Lafer B
    J Neural Transm (Vienna); 2018 Feb; 125(2):247-257. PubMed ID: 29177955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol).
    Ellegaard PK; Licht RW; Poulsen HE; Nielsen RE; Berk M; Dean OM; Mohebbi M; Nielsen CT
    Int J Bipolar Disord; 2018 Apr; 6(1):11. PubMed ID: 29619634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quetiapine: a review of its use in the management of bipolar depression.
    Sanford M; Keating GM
    CNS Drugs; 2012 May; 26(5):435-60. PubMed ID: 22519923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial.
    Zeinoddini A; Sorayani M; Hassanzadeh E; Arbabi M; Farokhnia M; Salimi S; Ghaleiha A; Akhondzadeh S
    Depress Anxiety; 2015 Mar; 32(3):167-73. PubMed ID: 25620378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials.
    Kishi T; Miyake N; Okuya M; Sakuma K; Iwata N
    Psychopharmacology (Berl); 2020 Nov; 237(11):3481-3487. PubMed ID: 32767039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder.
    Szegedi A; Durgam S; Mackle M; Yu SY; Wu X; Mathews M; Landbloom RP
    Am J Psychiatry; 2018 Jan; 175(1):71-79. PubMed ID: 28946761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
    Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
    J Affect Disord; 2018 Feb; 227():649-656. PubMed ID: 29174738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    Sachs GS; Ice KS; Chappell PB; Schwartz JH; Gurtovaya O; Vanderburg DG; Kasuba B
    J Clin Psychiatry; 2011 Oct; 72(10):1413-22. PubMed ID: 21672493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis.
    Cotton SM; Berk M; Watson A; Wood S; Allott K; Bartholomeusz CF; Bortolasci CC; Walder K; O'Donoghue B; Dean OM; Chanen A; Amminger GP; McGorry PD; Burnside A; Uren J; Ratheesh A; Dodd S
    Trials; 2019 Nov; 20(1):658. PubMed ID: 31779696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder.
    Calabrese JR; Bowden CL; Sachs G; Yatham LN; Behnke K; Mehtonen OP; Montgomery P; Ascher J; Paska W; Earl N; DeVeaugh-Geiss J;
    J Clin Psychiatry; 2003 Sep; 64(9):1013-24. PubMed ID: 14628976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder.
    Vieta E; Montgomery S; Sulaiman AH; Cordoba R; Huberlant B; Martinez L; Schreiner A
    Eur Neuropsychopharmacol; 2012 Nov; 22(11):825-35. PubMed ID: 22503488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.